Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Coupang Inc (CPNG) Price & Performance

ADMA Biologics Inc
Coupang Inc

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Coupang Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Coupang Inc trades at $18.9 (market cap $33.26B). The key difference: Coupang Inc is far larger — about 15.6× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.

ADMACPNG
Market Cap
$2.13B$33.26B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$33.53
52-Week Low
$7.60$15.12
Enterprise Value
$2.20B$32.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Coupang Inc

Coupang (CPNG) trades at $18.53, showing minimal daily movement (-0.16%) amid mixed technical signals. The stock maintains bullish moving averages but faces resistance near $20. Fundamentally, revenue growth remains strong at $34.53B (2025) though profitability is inconsistent with recent quarterly EPS misses. Regulatory challenges emerged with a $409 million data breach fine in June 2026, though investor sentiment improved as the penalty was below worst-case fears.

Wall Street maintains strong bullish consensus (87.5% buy ratings) with a $25.80 price target implying 39% upside. Key opportunities include sustained e-commerce growth and operational cash flow strength ($1.77B in 2025), while risks center on regulatory scrutiny, competitive pressures, and volatile profitability. The stock's high P/E (184.18) requires continued execution to justify valuation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG